HCPCS Level II code J7308 denotes aminolevulinic acid HCl 20% topical, single-unit formulation (354 mg), used as the photosensitizing agent in photodynamic therapy for cutaneous lesions. This code identifies the drug product component of topical photodynamic treatment and matters nationally because accurate coding drives appropriate billing for dermatologic procedures that pair the medication with light-based treatment. Proper use of J7308 affects reimbursement, claims processing, and clinical documentation across outpatient dermatology settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Readers will find a concise review of the clinical context for topical aminolevulinic acid, how the HCPCS Level II code is applied in practice, and the common sites of service for administration. The publication outlines typical linked services — for example, photodynamic therapy procedures — and identifies relevant diagnosis categories for use with the code.

The report provides benchmark and policy-oriented content useful for coding and billing teams, compliance officers, and dermatology providers: national coverage considerations, coding alignment with related procedural services, and practical notes on unitization and documentation expectations. Data not available in the input will be identified explicitly where applicable.